Skip to content
Licensed Unlicensed Requires Authentication Published by De Gruyter November 19, 2020

Comparative evaluation of the fully automated HemosIL® AcuStar ADAMTS13 activity assay vs. ELISA: possible interference by autoantibodies different from anti ADAMTS-13

  • Emanuela Falcinelli , Andrea Baccolo , Anna Maria Mezzasoma and Paolo Gresele EMAIL logo

Corresponding author: Paolo Gresele, MD, PhD, Department of Medicine, Division of Internal and Cardiovascular Medicine, University of Perugia, Centro didattico – Edificio B piano 1, Strada vicinale Via delle Corse, 06132 Perugia, Italy, Phone: +39/075 5783989, Fax: +39/075 5858439, E-mail:

  1. Research funding: None declared.

  2. Author contributions: All authors have accepted responsibility for the entire content of this manuscript and approved its submission.

  3. Competing interests: Authors state no conflict of interest.

  4. Informed consent: Informed consent was obtained from all individuals included in this study.

  5. Ethical approval: All the studies complied with local ethical rules and were carried out in accordance with the Helsinki declaration.


1. Kremer Hovinga, JA, Heeb, SR, Skowronska, M, Schaller, M. Pathophysiology of thrombotic thrombocytopenic purpura and hemolytic uremic syndrome. J Thromb Haemostasis 2018;16:618–29. in Google Scholar PubMed

2. Roriz, M, Landais, M, Desprez, J, Barbet, C, Azoulay, E, Galicier, L, et al.. Risk factors for autoimmune diseases development after thrombotic thrombocytopenic purpura. Medicine (Baltim) 2015;94:e1598. in Google Scholar PubMed PubMed Central

3. Yoshii, Y, Fujimura, Y, Bennett, CL, Isonishi, A, Kurumatani, N, Matsumoto, M. Implementation of a rapid assay of ADAMTS-13 activity was associated with improved 30-day survival rate in patients with acquired primary thrombotic thrombocytopenic purpura who received platelet transfusions. Transfusion 2017;57:2045–53. in Google Scholar PubMed

4. Just, S. Methodologies and clinical utility of ADAMTS-13 activity testing. Semin Thromb Hemost 2010;36:82–90. in Google Scholar PubMed

5. Peyvandi, F, Palla, R, Lotta, LA, Mackie, I, Scully, MA, Machin, SJ. ADAMTS-13 assays in thrombotic thrombocytopenic purpura. J Thromb Haemostasis 2010;8:631–40. in Google Scholar PubMed

6. Scully, M. Inhibitory anti-ADAMTS 13 antibodies: measurement and clinical application. Blood Rev 2010;24:11–6. in Google Scholar PubMed

7. Favresse, J, Lardinois, B, Chatelain, B, Jacqmin, H, Mullier, F. Evaluation of the fully automated HemosIL Acustar ADAMTS-13 activity assay. Thromb Haemostasis 2018;118:942–4. in Google Scholar PubMed

8. Valsecchi, C, Mirabet, M, Mancini, I, Biganzoli, M, Schiavone, L, Faraudo, S, et al.. Evaluation of a new, rapid, fully automated assay for the measurement of ADAMTS-13 activity. Thromb Haemostasis 2019;119:1767–72. in Google Scholar PubMed

9. Verbruggen, B. Diagnosis and quantification of factor VIII inhibitors. Haemophilia 2010;16:20–4. in Google Scholar PubMed

10. Chen, J, Chung, DW, Le, J, Ling, M, Konkle, BA, López, JA. Normal cleavage of von Willebrand factor by ADAMTS-13 in the absence of factor VIII in patients with severe hemophilia A. J Thromb Haemostasis 2013;11:1769–72. in Google Scholar PubMed PubMed Central

11. Rieger, M, Mannucci, PM, Kremer Hovinga, JA, Herzog, A, Gerstenbauer, G, Konetschny, C, et al.. ADAMTS13 autoantibodies in patients with thrombotic microangiopathies and other immunomediated diseases. Blood 2005;106:1262–7. in Google Scholar PubMed

Received: 2020-07-06
Accepted: 2020-10-25
Published Online: 2020-11-19
Published in Print: 2021-04-27

© 2020 Walter de Gruyter GmbH, Berlin/Boston

Downloaded on 21.2.2024 from
Scroll to top button